Thalidomide and rituximab in Waldenstrom macroglobulinemia

Blood

Volumn 112, Issue 12, 2008, Pages 4452-4457

  Treon, Steven P ^a,b   Soumerai, Jacob D ^a   Branagan, Andrew R ^a   Hunter, Zachary R ^a   Patterson, Christopher J ^a   Ioakimidis, Leukothea ^a   Briccetti, Frederick M ^c   Pasmantier, Mark ^d   Zimbler, Harvey ^e   Cooper, Robert B ^f   Moore, Maria ^g   Hill II, John ^h   Rauch, Alan ⁱ   Garbo, Lawrence ⁱ   Chu, Luis ^j   Chua, Cynthia ^k   Nantel, Stephen H ^l   Lovett, David R ^m   Boedeker, Hans ⁿ   Sonneborn, Henry ^o   Howard, John ^p   Musto, Paul ^q   Ciccarelli, Bryan T ^a   Hatjiharissi, Evdoxia ^a,b   Anderson, Kenneth C ^a,b   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c New Hampshire Hematology Oncology   (Canada)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^e Berkshire Hematology Oncology   (United States)

^f DANBURY HOSPITAL   (United States)

^g Park Ridge Hospital   (United States)

^h Hendersonville Hematology and Oncology at Pardee   (United States)

ⁱ New York Oncology Hematology   (United States)

^j Florida Cancer Specialists   (United States)

^k Oncology Hematology Care   (United States)

^l VANCOUVER GENERAL HOSPITAL   (Canada)

^m CAPE COD HOSPITAL   (United States)

ⁿ Bridgton Hospital   (United States)

^o Seacoast Cancer Center   (United States)

^p Virginia Oncology Associates   (United States)

^q Commonwealth Hematology Oncology ^*  (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN M; RITUXIMAB; THALIDOMIDE; ANTINEOPLASTIC AGENT; FC RECEPTOR; FCGR3A PROTEIN, HUMAN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRADYCARDIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HEART PALPITATION; HEMATOCRIT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; MALE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SOMNOLENCE; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; WALDENSTROEM MACROGLOBULINEMIA; ADJUVANT THERAPY; BLOOD; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; GENETICS; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; RECEPTORS, IGG; THALIDOMIDE; TREATMENT OUTCOME; WALDENSTROM MACROGLOBULINEMIA;

EID: 57649198069     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-04-150854     Document Type: Article

References (38)

1. Treon SP, Shima Y, Preffer FI, et al. Treatment of plasma cell dyscrasias by antibody immuno-therapy. Semin Oncol. 1999;26:97-106.
2. Treon SP, Kelliher A, Keele B, et al. Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic considerations and considerations. Semin Oncol. 2003;30:243-247.
3. Byrd JC, White CA, Link B, et al. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol. 1999;10:1525-1527.
4. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18:317-324.
5. Treon SP, Agus DB, Link B, et al. CD20 directed serotherapy induces responses and facilitates hematological recovery in patients with Waldenstrom's macroglobulinemia. J Immunother. 2001; 24:272-279.
6. Gertz MA, Rue M, Blood E, et al. Multicenter phase 2 trial of rituximab for Waldenstrom macro-globulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma. 2004;45:2047-2055.
7. Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol. 2002;20:2327-2333.
8. Treon SP, Emmanouilides C, Kimby E, et al. Extended rituximab therapy in Waldenström's macroglobulinemia. Ann Oncol. 2005;16:132-138.
9. Dimopoulos MA, Anagnostopoulos A, Zervas C, et al. Predictive factors for response to rituximab in Waldenstrom's macroglobulinemia. Clin Lymphoma. 2005;5:270-272.
10. Treon SP, Hansen M, Branagan AR, et al. Polymorphisms in Fc7RIIIA(CD16) receptor expression are associated with clinical responses to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol. 2005;23:474-481.
11. Treon SP, Gertz MA, Dimopoulos M, et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom's Macroglobulinemia. Blood. 2006;107:3442-3446.
12. Treon SP, Wasi P, Emmanouilides CA, et al. Combination therapy with rituximab and fludarabine is highly active in Waldenstrom's macroglobulinemia. Blood. 2002;100:211a.
13. Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R. Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30:243-247.
14. Tam CS, Wolf MM, Westerman D, et al. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma. 2005;6:136-139.
15. Hensel M, Villalobos M, Kornacker M, et al. Pentostatin/cyclophosphamide with or without ritux-imab: an effective regimen for patients with Waldenstrom's macroglobulinemia/ lymphoplasmacytic lymphoma. Clin Lymphoma Myeloma. 2005;6:131-135.
16. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab and cyclophosphamide. J Clin Oncol. 2007; 25:3344-3349.
17. Buske C, Dreyling MH, Eimermacher H, et al. Combined immuno-chemotherapy (R-CHOP) results in significantly superior response rates and time to treatment failure in first line treatment of patients with lymphoplasmacytoid/ic immunocytoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. Blood. 2004;104:162a.
18. Treon SP, Hunter Z, Branagan A. CHOP plus rit-uximab therapy in Waldenström's macroglobu-linemia. Clin Lymphoma Myeloma. 2005;5:273-277.
19. Leleu XP, Manning R, Soumerai JD, et al. Increased incidence of disease transformation and development of MDS/AML in Waldenstrom's macroglobulinemia patients treated with nucleoside analogues. Proc Am Soc Clin Oncol. 2007; 25[Suppl]:S445.
20. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210-216.
21. Janakiraman N, McLaughlin P, White CA, et al. Rituximab: correlation between effector cells and clinical activity in NHL. Blood. 1998;92:337a.
22. Gluck WL, Hurst D, Yuen A, et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion. Correlations with clinical response. Clin Cancer Res. 2004;10:2253-2264.
23. Khan KD, Emmanouilides C, Benson DM, et al. A phase 2 study of rituximab in combination inter-leukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. Clin Cancer Res. 2006;12: 7046-7053.
24. Hayashi T, Hideshima T, Akiyama M, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol. 2005;128:192-203.
25. Dimopoulos MA, Zomas A, Viniou NA, et al. Treatment of Waldenström's macroglobulinemia with thalidomide. J Clin Oncol. 2001;19:3596-3601.
26. Coleman M, Leonard J, Lyons L, et al. BLT-D (Biaxin, low dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrom's macroglobulinemia. Leuk Lymphoma. 2002;43: 1777-1782.
27. Dimopoulos MA, Tsatalas C, Zomas A, et al. Treatment of Waldenstrom's macroglobulinemia with single agent thalidomide or with combination of clarithromycin, thalidomide and dexamethasone. Semin Oncol. 2003;30:265-269.
28. Owen RG, Treon SP, Al-Katib A, et al. Clinico-pathological definition of Waldenström's macro-globulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenström's macroglobulinemia. Semin Oncol. 2003;30:110-115.
29. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Walden-ström's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenström's macroglobulinemia. Semin Oncol. 2003;30:116-120.
30. Kimby E, Treon SP, Anagnostopoulos A, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma. 2006;6:380-383.
31. Treon SP, Branagan AR, Hunter Z, et al. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macro-globulinemia. Ann Oncol. 2004;15:1481-1483.
32. Treon SP, Mitsiades C, Mitsiades N, et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in B-cell malignancies. J Immunotherapy. 2001;24:263-271.
33. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fcgamma RIIIA gene. Blood. 2002;99:754-758.
34. Ghobrial IM, Fonseca R, Greipp PR, et al. Initial immunoglobulin M "flare" after rituximab therapy in patients with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer. 2004;101:2593-2598.
35. Treon SP, Hatjiharissi E, Leleu X, et al. Novel agents in the treatment of Waldenstrom's macro-globulinemia. Clin Lymphoma Myeloma. 2007;5: 199-206.
36. Soumerai J, Branagan A, Hunter Z, Patterson C, Hatjiharissi E, Treon SP. Use of the immuno-modulators thalidomide and lenalidomide to augment rituximab clinical activity in Waldenstrom's macroglobulinemia. Haematologica. 2007;92:95.
37. Treon SP, Soumerai JD, Branagan AR, et al. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res. In press.
38. Zeldis J, Schafer PH, Bennett BL, Mercurio F, Stirling DI. Potential new therapeutics for Walden-strom's macroglobulinemia. Semin Oncol. 2003; 30:275-281.